Onconetix logo
Onconetix
ONCO | NASDAQ
Chart Builder DCF Calculator
$2.91
-$0.29 (-9.20%)
At close: Nov 16, 2026, 4:00 PM ET
$2.95
+$0.04 (+1.37%)
After-hours: Nov 16, 2026, 7:30 PM ET

Onconetix Company Profile

Company profile explained

Company Profile

Onconetix, Inc. operates as a biotechnology and pharmaceutical firm, committed to pioneering and bringing to market innovative treatments aimed at resolving critical health issues worldwide. The company's product lineup includes Entadfi, an FDA-cleared, once-daily oral medication. This prescription drug combines finasteride and tadalafil to manage benign prostatic hyperplasia (BPH). In its development pipeline, Onconetix is advancing a Streptococcus pneumoniae vaccine candidate, designed to prevent infectious middle ear infections in children and pneumonia in the elderly. Additionally, they are working on a universal influenza vaccine intended to provide comprehensive protection against all aggressive strains of the flu virus. Furthermore, Onconetix holds a license for an advanced norovirus S&P nanoparticle virus-like particle (VLP) vaccine platform from Cincinnati Children's. This adaptable platform is being leveraged to create vaccines for various infectious diseases, such as Marburg and monkeypox, among others. Established in 2018, the company was previously known as Blue Water Biotech, Inc., before changing its name to Onconetix, Inc. in December 2023. Its corporate headquarters are located in Cincinnati, Ohio.

Key Executives

Name Position
David Allan White Chief Executive Officer
Karina Fedasz Interim Chief Financial Officer
Ali I. Fattom Head of Science & Discovery
Andrew D. Skibo Global Head of Biologics Operations
Brian Price Head of Technology Strategy
Jay Newmark Chief Medical Officer
Theodore Scott Yoho Head of Business Development

Latest SEC Filings

Date Type Title
Nov 12, 2026 8-K Current Report
Nov 09, 2026 8-K Current Report
Nov 06, 2026 425 Filing
Nov 06, 2026 8-K Current Report
Nov 05, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Oct 27, 2026 425 Filing
Oct 26, 2026 8-K Current Report
Oct 23, 2026 DEFA14A Filing
Oct 23, 2026 8-K Current Report
Oct 23, 2026 425 Filing
View All SEC Filings ➞
Onconetix
Onconetix logo
Country United States
IPO Date Feb 18, 2022
Industry Biotechnology
Sector Healthcare
Employees 2
CEO David Allan White

Contact Details

201 East Fifth Street Cincinnati, Ohio 45202 United States

Stock Details

Ticker Symbol ONCO
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001782107
CUSIP Number 68237Q500
ISIN Number US68237Q5009
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.